Clinical Study
Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Table 1
Baseline clinical characteristics.
| | | PRP group | IVT group | IVB group | value |
| | Male : female | 16 : 4 | 14 : 6 | 15 : 5 | 0.77 | | Age mean (SD) | 55.10 (14.8) | 55.28 (13.5) | 53.77 (13.8) | 0.936 | | Type of diabetes 1 : 2 (no. of eyes) | 4 : 16 | 4 : 16 | 5 : 14 | 0.86 | | BCVA, mean no. of ETDRS letters (SD) | 67.35 (22.5) | 76.65 (9.99) | 75.53 (18.99) | 0.212 | | CMT mean (SD) | 342.05 (118.69) | 323.85 (157.33) | 309.05 (89.84) | 0.715 | | No. of new vessels | 3.45 (2.01) | 4.35 (3.32) | 4.79 (4.36) | 0.449 | | Mild PDR (no. of eyes) | 5 | 9 | 3 | — | | Moderate PDR (no. of eyes) | 10 | 6 | 9 | — | | High-risk PDR (no. of eyes) | 3 | 5 | 6 | — | | Advanced high-risk PDR (no. of eyes) | 2 | 0 | 2 | — | | BP (mmHg) | 135/82 | 135/81 | 126/77 | 0.25/0.18 | | Glycaemia (mg/dL) | 174.65 | 186.55 | 152.68 | 0.308 | | Cholesterol (mg/dL) | 200.1 | 196.3 | 196.15 | 0.967 | | LDL-Cholest. (mg/dL) | 133.26 | 125.72 | 126.88 | 0.86 | | HDL-Cholest. (mg/dL) | 41.94 | 43.21 | 49.44 | 0.105 | | Triglycerides (mg/dL) | 131.4 | 145.4 | 109.73 | 0.19 | | HbA1c | 8.325 | 8.315 | 7.87 | 0.65 |
|
|
BCVA: best-corrected visual acuity; BP: blood pressure; Cholest: cholesterol; CMT: central macular thickness; dL: decilitres; ETDRS: early treatment diabetic retinopathy study; HbA1c: glycosylated haemoglobin; HDL: high-density lipoproteins; IVB: intravitreal bevacizumab; IVT: intravitreal triamcinolone; LDL: low-density lipoproteins; mg: milligrams; mmHg: millimetres of mercury; no.: number; PDR: proliferative diabetic retinopathy; PRP: panretinal photocoagulation; SD: standard deviation. ANOVA was used to compare data among the groups.
|
